Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Brepocitinib→

Brepocitinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1883299-62-4
Molecular formula
C18H21F2N7O
Molecular weight
389.4 g/mol
Drug class
Investigational dual Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) inhibitor
Mechanism of action
Inhibits JAK1 and TYK2, reducing signalling downstream of cytokine receptors that use these kinases. This is a pharmacological description of the investigational molecule; it should not be represented as a currently authorised therapy or a product-specific clinical mechanism unless a marketing authorisation is confirmed.
Indications / reported uses
  • Investigated for dermatomyositis and other immune-mediated inflammatory diseases. The catalogue entry is not assigned an authorised therapeutic indication without a current product label or marketing authorisation.

Sources: ClinicalTrials.gov — Brepocitinib and dermatomyositis · PubMed — Brepocitinib JAK1/TYK2 pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Brepocitinib Environmental Risk Assessment (ERA) (the Brepocitinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.